(ILMN) Illumina - Ratings and Ratios

Illumina, Inc. (NASDAQ: ILMN) is a global leader in providing innovative sequencing- and array-based solutions for genetic and genomic analysis. The company operates across the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. Illuminas product portfolio includes advanced sequencing instruments like the NovaSeq and NextSeq series, as well as array-based solutions such as the iScan and HiScan systems. These platforms are complemented by a range of consumables, including reagents, flow cells, and library preparation kits. The company also offers specialized kits for whole-genome sequencing, targeted resequencing, and transcriptomic analysis, enabling researchers to study entire genomes, specific genes, or RNA regions of interest. Additionally, Illumina provides noninvasive prenatal testing (NIPT) solutions and comprehensive product support services.

Illumina serves a diverse customer base, including genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology firms, and consumer genomics companies. Its distribution network includes direct sales to customers and partnerships with life-science distributors. Founded in 1998 and headquartered in San Diego, California, Illumina has established itself as a pioneer in the field of genomics, driving advancements in cancer research, reproductive health, and precision medicine. The companys solutions are widely used in clinical and research settings, enabling breakthroughs in disease diagnosis, drug discovery, and personalized healthcare.

From a technical perspective, Illuminas stock (NASDAQ: ILMN) is currently trading at $74.35, below its 20-day SMA of $76.48 and 50-day SMA of $85.29. The stock is significantly below its 200-day SMA of $121.53, indicating a bearish trend. The Average True Range (ATR) of 3.88 suggests moderate volatility. Based on these indicators, the stock is expected to remain under pressure in the near term, with potential resistance at the 20-day SMA level.

Fundamentally, Illumina has a market capitalization of $11.39 billion, with a forward P/E ratio of 16.00, indicating expectations for future earnings growth. However, the current P/B ratio of 4.80 and P/S ratio of 2.61 suggest elevated valuations. The negative return on equity (RoE) of -45.06% reflects recent profitability challenges. Over the next three months, Illuminas stock is likely to face headwinds from macroeconomic uncertainties and valuation pressures, despite its strong market position in the genomics sector.